Short term efficacy of capacitive-resistive diathermy therapy in patients with low back pain: a prospective randomized controlled trial

A Notarnicola; G Maccagnano; M F Gallone; I Covelli; S Tafuri; B Moretti

doi:10.54517/jbrha4350

Publication Frequency

Quarterly since 2025

Journal Articles

Search scope

Journal Center

Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

more

Volume Arrangement

2025

Vol 39, No 3 (2025)

Vol 39, No 2 (2025)

Vol 39, No 1 (2025)

Featured Articles

Macrophages in the pathogenesis of psoriasis and anti-psoriatic nanotherapies

Psoriasis is a common, chronic, and inflammatory skin disease. Macrophages account for about 61.3% of the inflammatory cells infiltrating psoriatic lesions. Modulating macrophage polarization, inhibiting their infiltration, and targeting the secretion of inflammatory factors and associated inflammatory pathways by these cells can alleviate psoriasis symptoms and inflammation. Moreover, nanomaterials as novel drug carriers, offer unique advantages such as large surface area, easy modification, high biocompatibility, good biodegradability, enhanced systemic adsorption, etc. Nanomaterials have great potential for efficient drug delivery and release, as well as improving therapeutic efficacy while reducing adverse effects. By systematically addressing the role of macrophages in psoriasis pathogenesis and the potential of nanomaterials in treating psoriasis through modulating macrophages, this review enhances our understanding of the disease mechanism and holds promise for novel therapeutic breakthroughs and advancements in the future treatment of psoriasis.

Short term efficacy of capacitive-resistive diathermy therapy in patients with low back pain: a prospective randomized controlled trial

A Notarnicola, G Maccagnano, M F Gallone, I Covelli, S Tafuri, B Moretti

Article ID: 4350
Vol 31, Issue 2, 2017

DOI: https://doi.org/10.54517/jbrha4350

Received: 6 June 2022; Accepted: 6 June 2022; Available online: 6 June 2022; Issue release: 6 June 2022

Abstract

To compare the effectiveness of Doctor Tecar TherapyTM with that of laser therapy in the management of low back pain (LBP), a total of 60 patients with LBP were enrolled. The participants were randomly divided into two groups: a Tecar group (experimental group, 30 subjects), and a laser group (control group, 30 subjects). All the subjects received 10 sessions of therapy: one each day from Monday to Friday and the same again the following week. All the subjects were evaluated for pain (VAS) and disability (Roland and Morris score and Oswestry score) at baseline (T0), and 2 weeks (T1), 1 month (T2) and 2 months (T3) after the end of treatment. The pain and disability presented a trend to improvement over time in both groups. This improvement was statistically significant at all follow-ups (FUs) in the Tecar group but only at T1 for the Laser group (p less than 0.01). Comparing the two methods, there emerged a significant difference in favour of the Tecar group at T2 and T3 (p less than 0.01). The results show that Tecar therapy determined significant improvement already by the end of the treatment. Moreover, at the first and second month FUs, the Tecar therapy showed statistically better results than laser therapy

Keywords

Low back pain;diathermy;laser therapy

References

Supporting Agencies

This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Editor-in-Chief

Dr. Fabio Malavasi

Medical Genetics, University of Torino Medical School, Italy

Co-Editor-in-Chief

Prof. Marcello Iriti

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy

Indexing & Archiving

News & Announcements

2025-02-01

Notice of Change in Publication Schedule

In addition to the first issue that has already been published by the original publisher, there will be four more issues released this year, with scheduled publication dates in March, June, September, and December respectively.

2025-01-21

Notice: Ownership Transfer of the Journal

Starting from Volume 39 Issue 2 (2025), the ownership of Journal of Biological Regulators and Homeostatic Agents (ISSN: 0393-974X (P); 1724-6083 (O)) will be transferred from Biolife Sas to Asia Pacific Academy of Science Pte. Ltd. As of 21 January 2025, authors should make submissions to the new journal system and follow the author guidelines. Asia Pacific Academy of Science Pte. Ltd. will take over the publication of manuscripts being processed.

More Announcements...